Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457925 · ClinicalTrials.gov registry record · Phase 1
Absorption, Distribution, Metabolism And Excretion Study For GSK221149A
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00457925 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6 participants.
The verdict
NCT00457925, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.
Interventions
- DRUG GSK221149A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457925
The ClinicalTrials.gov registry entry for NCT00457925 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK221149A is the first listed.
NCT00457925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00457925 about?
NCT00457925 is a clinical study titled "Absorption, Distribution, Metabolism And Excretion Study For GSK221149A". This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.
What is the current status of trial NCT00457925?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-10.
What interventions are being tested in trial NCT00457925?
The interventions under investigation include: GSK221149A (DRUG).
Who is sponsoring clinical trial NCT00457925?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.